Cappuccini F, Yamamoto R S, DiSaia P J, Grosen E A, Gatanaga M, Lucci J A, Ininns E K, Gatanaga T, Granger G A
Department of Obstetrics and Gynecology, University of California, Irvine 92717.
Lymphokine Cytokine Res. 1991 Jun;10(3):225-9.
Ascites obtained from human ovarian cancer patients contains material(s) that inhibit the cytolytic activity of tumor necrosis factor (TNF) and lymphotoxin (LT) in vitro. These inhibitor(s) are found in ascites from ovarian cancer patients and are detected in very low amounts in the ascites from patients with nonmalignant hepatic disease. These ascites TNF/LT blocking factors are heat sensitive and heterogeneous with respect to molecular weight. Kinetic studies indicate these factors inhibited cytolysis at the stage of TNF/LT interaction with membrane receptors on L929 cells. Because TNF and LT are key cytokines in host cell-mediated antitumor mechanisms, factor(s) that inhibit these cytokines could have a profound effect on the tumor host interaction and their presence in the ascitic fluid, should be considered before designing clinical trials that employ intraperitoneal administration of TNF or LT for immunotherapy of ovarian cancer.
从人类卵巢癌患者腹水中获取的物质在体外可抑制肿瘤坏死因子(TNF)和淋巴毒素(LT)的细胞溶解活性。这些抑制剂存在于卵巢癌患者的腹水中,而在非恶性肝病患者的腹水中含量极低。这些腹水TNF/LT阻断因子对热敏感,且分子量不均一。动力学研究表明,这些因子在TNF/LT与L929细胞膜受体相互作用阶段抑制细胞溶解。由于TNF和LT是宿主细胞介导的抗肿瘤机制中的关键细胞因子,抑制这些细胞因子的因子可能会对肿瘤与宿主的相互作用产生深远影响,在设计采用腹腔内注射TNF或LT进行卵巢癌免疫治疗的临床试验之前,应考虑腹水液中这些因子的存在。